415 related articles for article (PubMed ID: 38164734)
21. Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.
Shemesh CS; Hsu JC; Hosseini I; Shen BQ; Rotte A; Twomey P; Girish S; Wu B
Mol Ther; 2021 Feb; 29(2):555-570. PubMed ID: 33038322
[TBL] [Abstract][Full Text] [Related]
22. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
Richard G; Princiotta MF; Bridon D; Martin WD; Steinberg GD; De Groot AS
Expert Rev Vaccines; 2022 Feb; 21(2):173-184. PubMed ID: 34882038
[TBL] [Abstract][Full Text] [Related]
23. Computational Prediction and Validation of Tumor-Associated Neoantigens.
Roudko V; Greenbaum B; Bhardwaj N
Front Immunol; 2020; 11():27. PubMed ID: 32117226
[TBL] [Abstract][Full Text] [Related]
24. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.
Cai Z; Su X; Qiu L; Li Z; Li X; Dong X; Wei F; Zhou Y; Luo L; Chen G; Chen H; Wang Y; Zeng Y; Liu X
Mol Cancer; 2021 Dec; 20(1):164. PubMed ID: 34903219
[TBL] [Abstract][Full Text] [Related]
25. Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.
Aurisicchio L; Salvatori E; Lione L; Bandini S; Pallocca M; Maggio R; Fanciulli M; De Nicola F; Goeman F; Ciliberto G; Conforti A; Luberto L; Palombo F
J Exp Clin Cancer Res; 2019 Feb; 38(1):78. PubMed ID: 30764846
[TBL] [Abstract][Full Text] [Related]
26. Methods behind neoantigen prediction for personalized anticancer vaccines.
Godazandeh K; Van Olmen L; Van Oudenhove L; Lefever S; Bogaert C; Fant B
Methods Cell Biol; 2024; 183():161-186. PubMed ID: 38548411
[TBL] [Abstract][Full Text] [Related]
27. Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy.
Wu Y; Feng L
Expert Opin Drug Deliv; 2023 Mar; 20(3):323-333. PubMed ID: 36634017
[TBL] [Abstract][Full Text] [Related]
28. Development of tumour peptide vaccines: From universalization to personalization.
Ma M; Liu J; Jin S; Wang L
Scand J Immunol; 2020 Jun; 91(6):e12875. PubMed ID: 32090366
[TBL] [Abstract][Full Text] [Related]
29. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
[TBL] [Abstract][Full Text] [Related]
30. Colorectal cancer vaccines: Tumor-associated antigens
Wagner S; Mullins CS; Linnebacher M
World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
[TBL] [Abstract][Full Text] [Related]
31. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
[TBL] [Abstract][Full Text] [Related]
32. Recent developments in neoantigen-based cancer vaccines.
Hodge K; Supabphol S; Kumar P; Poomipak W; Pisitkun T
Asian Pac J Allergy Immunol; 2020 Jun; 38(2):91-101. PubMed ID: 32563235
[TBL] [Abstract][Full Text] [Related]
33. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
[TBL] [Abstract][Full Text] [Related]
34. Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines.
Pounraj S; Chen S; Ma L; Mazzieri R; Dolcetti R; Rehm BHA
Cancer Res; 2024 Feb; 84(3):353-363. PubMed ID: 38055891
[TBL] [Abstract][Full Text] [Related]
35. Neoantigens in precision cancer immunotherapy: from identification to clinical applications.
Zhang Q; Jia Q; Zhang J; Zhu B
Chin Med J (Engl); 2022 Jun; 135(11):1285-1298. PubMed ID: 35838545
[TBL] [Abstract][Full Text] [Related]
36. The perfect personalized cancer therapy: cancer vaccines against neoantigens.
Aurisicchio L; Pallocca M; Ciliberto G; Palombo F
J Exp Clin Cancer Res; 2018 Apr; 37(1):86. PubMed ID: 29678194
[TBL] [Abstract][Full Text] [Related]
37. Sulfonium-Stapled Peptides-Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention.
Zhang Y; Jiang L; Huang S; Lian C; Liang H; Xing Y; Liu J; Tian X; Liu Z; Wang R; An Y; Lu F; Pan Y; Han W; Li Z; Yin F
Adv Sci (Weinh); 2024 Jun; 11(24):e2307754. PubMed ID: 38605600
[TBL] [Abstract][Full Text] [Related]
38. Peptide vaccines in early breast cancer.
Criscitiello C; Viale G; Curigliano G
Breast; 2019 Apr; 44():128-134. PubMed ID: 30769238
[TBL] [Abstract][Full Text] [Related]
39. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside.
Roy S; Sethi TK; Taylor D; Kim YJ; Johnson DB
J Leukoc Biol; 2020 Oct; 108(4):1455-1489. PubMed ID: 32557857
[TBL] [Abstract][Full Text] [Related]
40. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
